Siemens Introduces New Intelligent, Integrated IVD Solutions Virtually at EUROMEDLAB 2021
By LabMedica International staff writers Posted on 29 Nov 2021 |
Siemens Healthineers (Erlangen, Germany) introduced new intelligent, integrated IVD solutions virtually at the XXIV IFCCEFLM European Congress of Clinical Chemistry and Laboratory Medicine (EuroMedLab Congress 2021).
EuroMedLab Congress 2021 was to be held as an in-presence meeting between 28th of November and 2nd of December in Germany but was postponed after the country was hit very hard by a fourth wave of COVID-19. However, those interested participated virtually in the Siemens EUROMEDLAB Experience that showcased its latest innovations. Siemens offered a virtual booth tour, held product demonstrations, and hosted expert presentations and on-demand webinars.
At its virtual booth, Siemens demonstrated its Atellica Solution comprising flexible, scalable, automation-ready immunoassay and chemistry analyzers with integrated automation. The company also highlighted of its extensive Atellica portfolio of tests that deliver accurate, clinically relevant results, including SARS-CoV-2 antibody tests, COVID-19 antigen assay, Atellica IM B·R·A·H·M·S PCT Assay for early sepsis risk assessment, and proven, true high-sensitivity cardiac troponin I assays for managing chest pain patients. Siemens highlighted the Atellica CI 1900 System which is being developed for the lower-to-mid-volume laboratories. It is planned to utilize the same menu, reagents, consumables, and detection technology as the Atellica Solution. Siemens also demonstrated how its Atellica Diagnostics IT can help labs unify data and optimize workflow with simple, open, and scalable solutions.
Siemens held virtual product demonstrations of its new Atellica Hematology Portfolio which pairs automation, intelligence, and extended parameters to streamline operations and support accurate clinical decision-making. The company presented the Sysmex CN-3000 and CN-6000 fully automated, mid-and high-volume coagulation analyzers which combine size, speed, intelligence, and flexibility.
In addition, Siemens virtually demonstrated its epoc blood analysis system, a handheld, wireless solution to enable comprehensive blood analysis testing at the patient’s side on a single room temperature test card, with results in less than a minute. Visitors to its virtual booth also saw the DCA Vantage Analyzer that helps monitor glycemic control and detect early kidney disease in environments ranging from the physician’s office to remote, point-of-care coordinated sites in hospitals and multisite practices. Among other products, Siemens virtually demonstrated rapid clinical decision-making with lab-comparable results from its broad POC blood gas portfolio, its high-sensitivity troponin I testing solution, and the new Sysmex CN-3000 and CN-6000 Systems for accelerating hemostasis workflows.
Related Links:
Siemens Healthineers
Latest Molecular Diagnostics News
- Blood Proteins Could Warn of Cancer Seven Years before Diagnosis
- New DNA Origami Technique to Advance Disease Diagnosis
- Ultrasound-Aided Blood Testing Detects Cancer Biomarkers from Cells
- New Respiratory Syndromic Testing Panel Provides Fast and Accurate Results
- New Synthetic Biomarker Technology Differentiates Between Prior Zika and Dengue Infections
- Novel Biomarkers to Improve Diagnosis of Renal Cell Carcinoma Subtypes
- RNA-Powered Molecular Test to Help Combat Early-Age Onset Colorectal Cancer
- Advanced Blood Test to Spot Alzheimer's Before Progression to Dementia
- Multi-Omic Noninvasive Urine-Based DNA Test to Improve Bladder Cancer Detection
- First of Its Kind NGS Assay for Precise Detection of BCR::ABL1 Fusion Gene to Enable Personalized Leukemia Treatment
- Urine Test to Revolutionize Lyme Disease Testing
- Simple Blood Test Could Enable First Quantitative Assessments for Future Cerebrovascular Disease
- New Genetic Testing Procedure Combined With Ultrasound Detects High Cardiovascular Risk
- Blood Samples Enhance B-Cell Lymphoma Diagnostics and Prognosis
- Blood Test Predicts Knee Osteoarthritis Eight Years Before Signs Appears On X-Rays
- Blood Test Accurately Predicts Lung Cancer Risk and Reduces Need for Scans